GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Guangzhou Kingmed Diagnostics Group Co Ltd (SHSE:603882) » Definitions » Beneish M-Score

Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) Beneish M-Score : -2.98 (As of Apr. 23, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Guangzhou Kingmed Diagnostics Group Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.98 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Guangzhou Kingmed Diagnostics Group Co's Beneish M-Score or its related term are showing as below:

SHSE:603882' s Beneish M-Score Range Over the Past 10 Years
Min: -2.98   Med: -2.2   Max: 1.52
Current: -2.98

During the past 12 years, the highest Beneish M-Score of Guangzhou Kingmed Diagnostics Group Co was 1.52. The lowest was -2.98. And the median was -2.20.


Guangzhou Kingmed Diagnostics Group Co Beneish M-Score Historical Data

The historical data trend for Guangzhou Kingmed Diagnostics Group Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guangzhou Kingmed Diagnostics Group Co Beneish M-Score Chart

Guangzhou Kingmed Diagnostics Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.54 -2.00 -2.00 -1.73 -2.47

Guangzhou Kingmed Diagnostics Group Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.16 -2.47 -2.49 -2.46 -2.98

Competitive Comparison of Guangzhou Kingmed Diagnostics Group Co's Beneish M-Score

For the Diagnostics & Research subindustry, Guangzhou Kingmed Diagnostics Group Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guangzhou Kingmed Diagnostics Group Co's Beneish M-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Guangzhou Kingmed Diagnostics Group Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Guangzhou Kingmed Diagnostics Group Co's Beneish M-Score falls into.


;
;

Guangzhou Kingmed Diagnostics Group Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Guangzhou Kingmed Diagnostics Group Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0392+0.528 * 1.071+0.404 * 1.0992+0.892 * 0.8195+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.5497+4.679 * -0.079587-0.327 * 0.9445
=-2.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Total Receivables was ¥5,272 Mil.
Revenue was 1737.946 + 2039.645 + 1841.261 + 2230.006 = ¥7,849 Mil.
Gross Profit was 626.332 + 758.114 + 590.81 + 752.709 = ¥2,728 Mil.
Total Current Assets was ¥7,603 Mil.
Total Assets was ¥10,978 Mil.
Property, Plant and Equipment(Net PPE) was ¥2,150 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥690 Mil.
Total Current Liabilities was ¥2,321 Mil.
Long-Term Debt & Capital Lease Obligation was ¥572 Mil.
Net Income was 4.189 + 108.287 + -18.637 + 67.365 = ¥161 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was 277.633 + 172.593 + -138.311 + 723.009 = ¥1,035 Mil.
Total Receivables was ¥6,191 Mil.
Revenue was 2001.11 + 2190.945 + 2117.566 + 3268.161 = ¥9,578 Mil.
Gross Profit was 691.775 + 867.687 + 802.92 + 1202.959 = ¥3,565 Mil.
Total Current Assets was ¥8,602 Mil.
Total Assets was ¥12,163 Mil.
Property, Plant and Equipment(Net PPE) was ¥2,325 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥543 Mil.
Total Current Liabilities was ¥2,947 Mil.
Long-Term Debt & Capital Lease Obligation was ¥447 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(5271.904 / 7848.858) / (6190.708 / 9577.782)
=0.671678 / 0.646361
=1.0392

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(3565.341 / 9577.782) / (2727.965 / 7848.858)
=0.372251 / 0.347562
=1.071

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (7602.529 + 2149.531) / 10978.237) / (1 - (8602.263 + 2324.879) / 12163.052)
=0.111692 / 0.101612
=1.0992

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=7848.858 / 9577.782
=0.8195

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 2324.879)) / (0 / (0 + 2149.531))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(689.9 / 7848.858) / (543.242 / 9577.782)
=0.087898 / 0.056719
=1.5497

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((572.297 + 2320.85) / 10978.237) / ((447.198 + 2946.558) / 12163.052)
=0.263535 / 0.279022
=0.9445

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(161.204 - 0 - 1034.924) / 10978.237
=-0.079587

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Guangzhou Kingmed Diagnostics Group Co has a M-score of -2.98 suggests that the company is unlikely to be a manipulator.


Guangzhou Kingmed Diagnostics Group Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Guangzhou Kingmed Diagnostics Group Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Guangzhou Kingmed Diagnostics Group Co Business Description

Traded in Other Exchanges
N/A
Address
International Biological Island spiral three on the 10th, Guangdong Province, Guangzhou, CHN, 510000
Founded in 1994, KingMed is the largest independent clinical laboratory in China. It was listed on the Shanghai Stock Exchange in 2017. As of 2023, KingMed has 49 centralized labs and provides over 4000 test items. Over 90% of its total revenue comes from clinical diagnostics. Furthermore, KingMed has been actively investing in its cold chain logistics. Its service network covers the most intensely populated areas in China.
Executives
Hao Bi Xi Directors, senior managers
Wang Ling Lai Director
Yu Shi Hui senior management
Liang Yao Ming Director
Peng Yong Xiang Director

Guangzhou Kingmed Diagnostics Group Co Headlines

No Headlines